BR112012001931A2 - métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv - Google Patents

métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv

Info

Publication number
BR112012001931A2
BR112012001931A2 BR112012001931A BR112012001931A BR112012001931A2 BR 112012001931 A2 BR112012001931 A2 BR 112012001931A2 BR 112012001931 A BR112012001931 A BR 112012001931A BR 112012001931 A BR112012001931 A BR 112012001931A BR 112012001931 A2 BR112012001931 A2 BR 112012001931A2
Authority
BR
Brazil
Prior art keywords
diagnosing
outcome
methods
infected patients
hcv infected
Prior art date
Application number
BR112012001931A
Other languages
English (en)
Portuguese (pt)
Inventor
Pierre-Yves Bochud
Andri Rauch
Original Assignee
Centre Hospitalier Univ Vaudois
Univ Of Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ Vaudois, Univ Of Bern filed Critical Centre Hospitalier Univ Vaudois
Publication of BR112012001931A2 publication Critical patent/BR112012001931A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012001931A 2009-07-31 2010-07-09 métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv BR112012001931A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH12012009 2009-07-31
US28253810P 2010-02-26 2010-02-26
PCT/IB2010/053139 WO2011013019A1 (en) 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients

Publications (1)

Publication Number Publication Date
BR112012001931A2 true BR112012001931A2 (pt) 2017-07-18

Family

ID=42727569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001931A BR112012001931A2 (pt) 2009-07-31 2010-07-09 métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv

Country Status (10)

Country Link
US (1) US20110165124A1 (https=)
EP (1) EP2459210A1 (https=)
JP (1) JP2013500713A (https=)
KR (1) KR20120040725A (https=)
CN (1) CN102665753A (https=)
AU (1) AU2010277239A1 (https=)
BR (1) BR112012001931A2 (https=)
CA (1) CA2768772A1 (https=)
MX (1) MX2012001058A (https=)
WO (1) WO2011013019A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656159B2 (ja) * 2009-08-24 2015-01-21 独立行政法人理化学研究所 インターフェロン療法の効果予測用マーカー
CN102770557B (zh) * 2009-12-22 2015-08-19 爱尔兰詹森科学公司 关于对聚乙二醇干扰素和利巴韦林应答的与预治疗血清ip-10定量结合的il28b基因多态性的预测值相比这些生物标记中任何单独一种增强
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
MX2013011256A (es) * 2011-03-31 2013-10-17 Novartis Ag Alisporivir para el tratamiento de la infeccion por el virus de hepatitis c.
EP2726632A1 (en) * 2011-06-30 2014-05-07 Centre Hospitaller Universitaire Vaudois (CHUV) Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
WO2013017653A1 (en) 2011-08-03 2013-02-07 Cytheris Hcv immunotherapy
JP2013074888A (ja) * 2011-09-15 2013-04-25 Arkray Inc IL28B(rs8099917)とITPA(rs1127354)の変異を検出する方法
US20140271542A1 (en) * 2011-10-05 2014-09-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Service Genetic marker for predicting prognosis in patients infected with hepatitis c virus
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9678074B2 (en) 2012-03-28 2017-06-13 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Interferon-λ4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN108220424A (zh) * 2018-02-05 2018-06-29 广州和康医疗技术有限公司 一种检测il28基因位点的方法及试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001050A (en) 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5888780A (en) 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
WO1997001603A1 (en) 1995-06-26 1997-01-16 Henkel Corporation Methods of preparing inorganic pigment dispersions
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
JP3662850B2 (ja) 1998-06-24 2005-06-22 イルミナ インコーポレイテッド 微小球を有するアレイセンサーのデコード
GB9817266D0 (en) 1998-08-07 1998-10-07 Imperial College Method
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
JP2005204549A (ja) * 2004-01-21 2005-08-04 Hubit Genomix Inc C型肝炎ウイルス感染者の経過に関する遺伝子およびその利用
CA2572569A1 (en) * 2004-07-01 2006-01-12 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods and kits for predicting liver fibrosis progression rate in chronic hepatitis c patients
JP2012501345A (ja) * 2008-08-28 2012-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド Hcv遺伝子型の分析
EP2432898B1 (en) * 2009-05-21 2014-11-26 Merck Sharp & Dohme Corp. Genetic markers associated with interferon-alpha response

Also Published As

Publication number Publication date
CN102665753A (zh) 2012-09-12
KR20120040725A (ko) 2012-04-27
JP2013500713A (ja) 2013-01-10
AU2010277239A1 (en) 2012-02-02
WO2011013019A1 (en) 2011-02-03
CA2768772A1 (en) 2011-02-03
MX2012001058A (es) 2012-06-19
US20110165124A1 (en) 2011-07-07
EP2459210A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
BR112012001931A2 (pt) métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv
BR112012000352A2 (pt) tapete ou tapete em placas
HRP20180572T1 (hr) 1' -supstituirani karba-nukleozidni analozi za antivirusnu terapiju
BRPI1015379A2 (pt) sistemas de cálculo biométrico e métodos
EP2320045A4 (en) APPARATUS FOR TREATING EXHAUST GAS
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
BR112012029417A2 (pt) detecção de análise de ataques maliciosos
EP4024013C0 (en) ANALYSIS SYSTEM
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
HUE051377T2 (hu) Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére
BRPI0906858A2 (pt) Métodos para detecção de assinaturas de doença ou condições em fluidos corporais
IL216472A0 (en) Benzoxazepines based p13k/mtor inhibitors against proliferative diseases
DK2286156T3 (da) Datacenter med gulvvarme
IT1400425B1 (it) Modified snrnas for use in therapy.
BR112012020718A2 (pt) complexo de metal-ligante e catalisador
BR112013014063A2 (pt) inibidores macrocíclicos do vírus flaviviridae
BRPI0910854A2 (pt) métodos de tratamento
PT3412687T (pt) Métodos de tratamento de dlbcl
BR112013008905A2 (pt) mecanismo de dosagem e método de dosagem
BR112012005438A2 (pt) inibidores de vírus flaviviridae
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BRPI1006988A2 (pt) mecanismo antitrapaça baseado em entidade confiável
PL2594588T3 (pl) Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
BRPI1015209A2 (pt) placa de osteossíntese com recurso de microincisões
BR112012003844A2 (pt) vacinas de pttv e diagnóstico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]